Susan Dorman to Cost-Benefit Analysis
This is a "connection" page, showing publications Susan Dorman has written about Cost-Benefit Analysis.
Connection Strength
0.443
-
Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. AIDS. 2013 Nov 28; 27(18):2883-92.
Score: 0.097
-
QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. BMC Infect Dis. 2012 Dec 19; 12:360.
Score: 0.091
-
Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One. 2008; 3(12):e4057.
Score: 0.069
-
Cost-effectiveness of different strategies for amplified Mycobacterium tuberculosis direct testing for cases of pulmonary tuberculosis. J Clin Microbiol. 2008 Nov; 46(11):3811-2.
Score: 0.068
-
Cost-effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J Clin Microbiol. 2003 Mar; 41(3):948-53.
Score: 0.046
-
Cost-effectiveness of routine diagnostic evaluation of pulmonary tuberculosis in a primary care unit in Brazil. Int J Tuberc Lung Dis. 2013 Oct; 17(10):1336-40.
Score: 0.024
-
The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis. 2013 Aug; 57(4):532-42.
Score: 0.023
-
Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults. Int J Tuberc Lung Dis. 2013 Apr; 17(4):552-8.
Score: 0.023